J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study fail

John­son & John­son scrapped its Phase 3 pro­gram for at­i­caprant, an ex­per­i­men­tal and new type of ma­jor de­pres­sive dis­or­der drug, fol­low­ing “in­suf­fi­cient ef­fi­ca­cy,” the phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.